Close

Teva Pharma (TEVA): Concerns on Generics Overdone - Guggenheim

Go back to Teva Pharma (TEVA): Concerns on Generics Overdone - Guggenheim

Teva Reports Third Quarter 2016 Results

November 15, 2016 7:00 AM EST

Results include the generic business of Actavis, since August 2; Provides updated outlook for 2016.

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended September 30, 2016.

           

Q3 2016

Revenues $5.6 billion Cash flow from operations $1.5 billion GAAP EPS $0.35... More